01/19/21 4:01 PMNasdaq : BBIOStockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) and Eidos Therapeutics, Inc. ("Eidos") (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related toRHEA-AIpositive
01/13/21 4:30 PMNasdaq : BBIOBridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for MergerBridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) and Eidos Therapeutics, Inc. ("Eidos") (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, onRHEA-AIneutral
01/06/21 4:30 PMNasdaq : BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio's board of directors granted six new employeesRHEA-AIvery positive
01/04/21 7:30 AMNasdaq : BBIOLeading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote "FOR" Proposed MergerBridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services ("ISS") recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote " FOR "RHEA-AIpositive
12/23/20 7:30 AMNasdaq : BBIOUCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic DiseasesUC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients. "The BridgeBio team isRHEA-AIvery positive
12/07/20 8:30 AMNasdaq : BBIOBridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular DiseaseContour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise Partnership Focused on Deliver ing Target ed Therap ies for Genetically Defined Cardiovascular Disease s PALO ALTO, Calif. and SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBERHEA-AIpositive
12/04/20 4:30 PMNasdaq : BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1, 2020, the compensation committee of BridgeBio's board of directors granted 15 new employeesRHEA-AIvery positive
12/01/20 7:30 AMNasdaq : BBIOBridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinomao Application accepted under P riority R eview designation o Application accepted into Real Time Oncology Review (RTOR) pilot program o This is BridgeBio's s econd NDA a cceptance o Application will also be submitted for review in Australia and Canada under Project Orbis PALO ALTO, Calif., Dec.RHEA-AIneutral
11/13/20 7:30 AMNasdaq : BBIOBridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase MutationsBridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPKRHEA-AIneutral
11/05/20 7:30 AMNasdaq : BBIOBridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update- Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio's clinical and commercial development infrastructure to bear upon Eidos' Acoramidis - New Drug Application f or Fosdenopterin f or t he t reatment o f MoCD Type A accepted by the FDA under PriorityRHEA-AIneutral
